Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902).
Tomono KawaseHiroshi ImamuraRyohei KawabataJin MatsuyamaKazuhiro NishikawaKazuhiro YanagiharaKazuyoshi YamamotoNoriyuki HokiJunji KawadaHisato KawakamiDaisuke SakaiYukinori KurokawaToshio ShimokawaTaroh SatohPublished in: International journal of clinical oncology (2024)
These findings indicate that S-1 plus docetaxel as first-line treatment for older patients is feasible and that it has promising efficacy against advanced gastric cancer.